Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection
IRCT20200217046526N1Phase 2Completed
- Sponsor
- ACECR
- Start
- Mar 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, single-arm trial of mesenchymal stem cell therapy (Hexun Biosciences) in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19), sponsored by ACECR. Started Mar 2020; status: completed.
02
Drugs
mesenchymal stem cell therapy (Hexun Biosciences)
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200217046526N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200217046526N1.